Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 6, pp 911–916 | Cite as

Potential for simplification of HIV treatment with boosted protease inhibitor monotherapy

  • Elena ReinaEmail author
  • Ramón San Miguel
  • Natalia Larrea
  • Patricia Garcia
  • Victor Napal
Research Article

Abstract

Background Previous studies have evaluated the simplification of HIV treatment with ritonavir-boosted protease inhibitor monotherapy, demonstrating acceptable efficacy and advantages such as avoidance of the adverse effects of reverse transcriptase inhibitors. To achieve the best results, patients should be appropriately selected for this therapy. Objective The purpose of this study was to estimate the proportion of HIV patients suitable for boosted protease inhibitor monotherapy according to clinical trial criteria. Setting The study was conducted in the outpatient hospital pharmacy service of the Complejo Hospitalario de Navarra in northern Spain. Method A retrospective analysis was performed on data from 635 adults on antiretroviral therapy. The eligibility criteria were: (1) >18 years of age; (2) prior triple-drug antiretroviral regimen; (3) durability of current treatment >18 months; (4) viral load <400 copies/mL over the 18 months before evaluation and <50 copies/mL over the last 6 months; (5) CD4 count ≥250 cells/μL; (6) CD4 count nadir >100 cells/μL; (7) no previous virological failure under prior protease inhibitor-based regimen; (8) absence of co-infection with hepatitis B virus; (9) absence of HIV-related neurological disease; and (10) adherence >95 %. The average cost of the current treatment was calculated for patients who met all criteria, as well as the potential economic impact of simplification to monotherapy. Main outcome measure Number of patients meeting all criteria for simplification to monotherapy according to clinical trial standards. Results One hundred and three patients (16.5 %) met the clinical trial criteria for protease inhibitor monotherapy. One hundred and fifty patients (24 %) failed to fulfil only one of the conditions. Fifty-four percent of the patients who met all of the criteria had been treated for more than 10 years. The average saving per patient per year was €2,850–€3,400. Conclusion This treatment strategy represents a realistic, albeit minority, option. Fulfilment of the above conditions should be the basis for simplification to protease inhibitor monotherapy, though the final decision depends on clinical criteria and patient preferences assessed by the attending physician. Further studies are needed to confirm long-term safety and efficacy.

Keywords

AIDS Antiretrovirals Boosted protease inhibitors HIV infection Monotherapy 

Notes

References

  1. 1.
    Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. 2012. http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 2 Apr 2012.
  2. 2.
    Thompson MA, Aberg JA, Cahn P, Montaner JSG, Rizzardini G, Telenti A, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA. 2010;304(3):321–33.PubMedCrossRefGoogle Scholar
  3. 3.
    European AIDS Clinical Society (EACS). European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults. 2011. http://www.europeanaidsclinicalsociety.org/index.php?option=com_content&view=article&id=59:eacs-guidelines&catid=37:guidelines&Itemid=41. Accessed 2 Apr 2012.
  4. 4.
    Spanish AIDS Study Group (GESIDA) and the National AIDS Plan. National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus. 2012. http://www.gesida-seimc.org/pcientifica/fuentes/DcyRc/gesidadcyrc2012-Documentoconsenso-TAR-adulto-verordenador.pdf. Accessed 2 Apr 2012.
  5. 5.
    Arribas JR, Horban A, Gerstoft J, Fätkenheuer G, Nelson M, Clumeck N, et al. The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml. AIDS. 2010;24(2):223–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, et al. Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS. 2010;24(15):2365–74.PubMedGoogle Scholar
  7. 7.
    Arribas JR, Delgado R, Arranz A, Muñoz R, Portilla J, Pasquau J, et al. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and 2 nucleosides for maintenance therapy of HIV: 96-week analysis. J Acquir Immune Defic Syndr. 2009;51(2):147–52.PubMedCrossRefGoogle Scholar
  8. 8.
    Pulido F, Matarranz M, Rodriguez-Rivera V, Fiorante S, Hernando A. Boosted protease inhibitor monotherapy. What have we learnt after seven years of research? AIDS Rev. 2010;12(3):127–34. Epub 2010/09/16.Google Scholar
  9. 9.
    Pulido Ortega F, Llenas-Garcia J. Lopinavir/ritonavir monotherapy as a simplification strategy in the treatment of HIV-1 infection. Enferm Infecc Microbiol Clin. 2008;26(Suppl 16):12–20. Epub 2009/07/03.Google Scholar
  10. 10.
    Valencia-Ortega ME, Moreno-Celda V. From research to clinical practice: use of lopinavir/ritonavir in monotherapy. Enferm Infecc Microbiol Clin. 2008;26(10):671–2.PubMedCrossRefGoogle Scholar
  11. 11.
    Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice. J Antimicrob Chemother. 2007;60(2):436–9.PubMedCrossRefGoogle Scholar
  12. 12.
    Pierone G, Mieras J, Bulgin-Coleman D, Kantor C, Shearer J, Fontaine L, et al. A pilot study of switch to lopinavir/ritonavir (LPV/r) monotherapy from nonnucleoside reverse transcriptase inhibitor-based therapy. HIV Clin Trials. 2006;7(5):237–45.PubMedCrossRefGoogle Scholar
  13. 13.
    González Rivas L, Sánchez Gómez E, Sánchez del Moral R, Grutzmancher Saiz S, Pujol de la Llave E, Bocanegra Martín C. Simplification of antiretroviral therapy: a good choice for our patients and the sustainability of our health care system. Farm Hosp. 2011;35(6):317–21.PubMedCrossRefGoogle Scholar
  14. 14.
    Sahali S, Chaix ML, Delfraissy JF, Ghosn J. Ritonavir-boosted protease inhibitor monotherapy for the treatment of HIV-1 infection. AIDS Rev. 2008;10(1):4–14.PubMedGoogle Scholar
  15. 15.
    Nunes EP, Santini de Oliveira M, Merçon M, Zajdenverg R, Faulhaber JC, Pilotto JH, et al. Monotherapy with lopinavir/ritonavir as maintenance after HIV-1 viral suppression: results of a 96-week randomized, controlled, open-label, pilot trial (KalMo study). HIV Clin Trials. 2009;10(6):368–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, et al. Longterm (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial. HIV Med. 2010;11(2):137–42.PubMedCrossRefGoogle Scholar
  17. 17.
    Pulido F, Serrano O, Rivero A. Atazanavir/ritonavir monotherapy for maintenance of virologic suppression: 48 week primary analysis of the 96 week multicenter, open-label, single-arm, pilot OREY Study. In: Gazzard B, Lundgren J, editors. Abstracts of the 12th European AIDS conference/EACS, 11–14 Nov 2009, Cologne. HIV Med. 2009;10(Suppl 2):1–246.Google Scholar
  18. 18.
    Swindells S, DiRienzo AG, Wilkin T, Fletcher CV, Margolis DM, Thal GD, et al. Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. JAMA. 2006;296(7):806–14.PubMedCrossRefGoogle Scholar
  19. 19.
    Knobel H, Escobar I, Polo R, Ortega L, Martín-Conde MT, Casado JL, et al. Recommendations from GESIDA/SEFH/PNS to improve adherence to antiviral treatment (2004). Enferm Infecc Microbiol Clin. 2005;23(4):221–31.PubMedCrossRefGoogle Scholar
  20. 20.
    Flandre P, Delaugerre C, Ghosn J, Chaix ML, Horban A, Girard PM, et al. Prognostic factors for virological response in antiretroviral therapy-naïve patients in the MONARK Trial randomized to ritonavir-boosted lopinavir alone. Antivir Ther. 2009;14(1):93–7.PubMedGoogle Scholar
  21. 21.
    Campo RE, Da Silva BA, Cotte L, Gathe JC, Gazzard B, Hicks CB, et al. Predictors of loss of virologic response in subjects who simplified to lopinavir/ritonavir monotherapy from lopinavir/ritonavir plus zidovudine/lamivudine. AIDS Res Hum Retroviruses. 2009;25(3):269–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Ibarra Barrueta O, Ortega Valín L, Grupo VIH de la SEFH. Survey of the pharmaceutical care situation of the HIV patient in Spain. Farm Hosp. 2008;32(3):170–7.Google Scholar
  23. 23.
    Inciardi JF, Leeds AL. Assessing the utility of a community pharmacy refill record as a measure of adherence and viral load response in patients infected with human immunodeficiency virus. Pharmacotherapy. 2005;25(6):790–6.PubMedCrossRefGoogle Scholar
  24. 24.
    Alberts B. Science breakthroughs. Science. 2011;334(6063):1604.PubMedCrossRefGoogle Scholar
  25. 25.
    Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d’Arminio Monforte A, et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS. 2003;17(8):1179–93.PubMedCrossRefGoogle Scholar
  26. 26.
    Saez de la Fuente J, Such Díaz A, Sánchez Gil C, Esteban Alba C, Escobar Rodríguez I. Meta-analysis of the effectiveness of the strategy of monotherapy with boosted protease inhibitors in HIV+ patients. Farm Hosp. 2010;34(5):251–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Mathis S, Khanlari B, Pulido F, Schechter M, Negredo E, Nelson M, et al. Effectiveness of protease inhibitor monotherapy versus combination antiretroviral maintenance therapy: a meta-analysis. PLoS ONE. 2011;6(7):e22003.PubMedCrossRefGoogle Scholar
  28. 28.
    Perez-Valero I, Arribas JR. Protease inhibitor monotherapy. Curr Opin Infect Dis. 2011;24(1):7–11. Epub 2010/12/15.Google Scholar
  29. 29.
    Arribas JR, Pulido F, Lázaro P, Méndez I. Estudio farmacoeconómico de lopinavir/ritonavir en monoterapia en el ensayo clínico OK04. PharmacoEconomics—Spanish Research Articles. 2011;8(3):85–97.Google Scholar
  30. 30.
    Pasquau J, Gostkorzewicz J, Ledesma F, Anceau A, Hill A, Moecklinghoff C. Budget impact analysis of switching to darunavir/ritonavir monotherapy for HIV-infected people in Spain. Appl Health Econ Health Policy. 2012;10(2):139–41.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Elena Reina
    • 1
    Email author
  • Ramón San Miguel
    • 1
  • Natalia Larrea
    • 1
  • Patricia Garcia
    • 1
  • Victor Napal
    • 1
  1. 1.Department of Pharmacy ServicesComplejo Hospitalario de NavarraPamplonaSpain

Personalised recommendations